Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy
Shuo Yang, Si-Qi Ma, Xing Wan, Heng He, Han Pei, Min-Jian Zhao, Chen Chen, Dao-Wen Wang, Xiao-Yan Dong, Jia-Jia Yuan, Bin Li, Shuo Yang, Si-Qi Ma, Xing Wan, Heng He, Han Pei, Min-Jian Zhao, Chen Chen, Dao-Wen Wang, Xiao-Yan Dong, Jia-Jia Yuan, Bin Li
Abstract
Leber's hereditary optic neuropathy (LHON) is a disease that leads to blindness. Gene therapy has been investigated with some success, and could lead to important advancements in treating LHON. This was a prospective, open-label trial involving 9 LHON patients at Tongji Hospital, Wuhan, China, from August 2011 to December 2015. The purpose of this study was to evaluate the long-term outcomes of gene therapy for LHON. Nine LHON patients voluntarily received an intravitreal injection of rAAV2-ND4. Systemic examinations and visual function tests were performed during the 36-month follow-up period to determine the safety and efficacy of this gene therapy. Based on successful experiments in an animal model of LHON, 1 subject also received an rAAV2-ND4 injection in the second eye 12months after gene therapy was administered in the first eye. Recovery of visual acuity was defined as the primary outcome of this study. Changes in the visual field, visual evoked potential (VEP), optical coherence tomography findings, liver and kidney function, and antibodies against AAV2 were defined as secondary endpoints. Eight patients (Patients 2-9) received unilateral gene therapy and visual function improvement was observed in both treated eyes (Patients 4, 6, 7, and 8) and untreated eyes (Patients 2, 3, 4, 6 and 8). Visual regression fluctuations, defined as changes in visual acuity greater than or equal to 0.3 logMAR, were observed in Patients 2 and 9. Age at disease onset, disease duration, and the amount of remaining optic nerve fibers did not have a significant effect on the visual function improvement. The visual field and pattern reversal VEP also improved. The patient (Patient 1) who received gene therapy in both eyes had improved visual acuity in the injected eye after the first treatment. Unfortunately, visual acuity in this eye decreased 3months after he received gene therapy in the second eye. Animal experiments suggested that ND4 expression remains stable in the contralateral eye after intravitreal injections. No serious safety problem was observed in the 3-year follow-up of the 9 participants enrolled in this virus-based gene therapy. Meanwhile, our results support the use of intravitreal rAAV2-ND4 as an aggressive maneuver in our clinical trial. Further study in additional patients and in these 9 subjects is needed to better understand the effects of rAAV2-ND4 gene therapy on LHON and to increase the applications of this technique.
Keywords: Best-corrected visual acuity; Gene therapy; Leber's hereditary optic neuropathy.
Copyright © 2016 The Ohio State University Wexner Medical Center. Published by Elsevier B.V. All rights reserved.
Figures
References
- Bainbridge J.W., Smith A.J., Barker S.S. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008;358:2231–2239.
- Bainbridge J.W., Mehat M.S., Sundaram V. Long-term effect of gene therapy on Leber's congenital amaurosis. N. Engl. J. Med. 2015;372:1887–1897.
- Barboni P., Savini G., Feuer W.J. Retinal nerve fiber layer thickness variability in Leber hereditary optic neuropathy carriers. Eur. J. Ophthalmol. 2012;22:985–991.
- Beck R.W., Moke P.S., Turpin A.H. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J. Ophthalmol. 2003;135:194–205.
- Cui G., Ding H., Xu Y., Li B., Wang D.W. Applications of the method of high resolution melting analysis for diagnosis of Leber's disease and the three primary mutation spectrum of LHON in the Han Chinese population. Gene. 2013;512:108–112.
- Cwerman-Thibault H., Augustin S., Ellouze S., Sahel J.A., Corral-Debrinski M. Gene therapy for mitochondrial diseases: Leber hereditary optic neuropathy as the first candidate for a clinical trial. C. R. Biol. 2014;337:193–206.
- Feuer W.J., Schiffman J.C., Davis J.L. Gene therapy for Leber hereditary optic neuropathy: initial results. Ophthalmology. 2016;123:558–570.
- Gao J., Shi H., Pei Z. Comparison of immunosuppressive effects and ND4 expression among different immunosuppressive strategies following AAV2-ND4 gene treatment for Leber hereditary optic neuropathy. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013;42:187–191.
- Klopstock T., Yu-Wai-Man P., Dimitriadis K. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134:2677–2686.
- Lam B.L., Feuer W.J., Schiffman J.C. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial. JAMA Ophthalmol. 2014;132:428–436.
- Luo X., Salgueiro Y., Beckerman S.R., Lemmon V.P., Tsoulfas P., Park K.K. Three-dimensional evaluation of retinal ganglion cell axon regeneration and pathfinding in whole mouse tissue after injury. Exp. Neurol. 2013;247:653–662.
- Mackey D.A., Oostra R.J., Rosenberg T. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am. J. Hum. Genet. 1996;59:481–485.
- Maguire A.M., Simonelli F., Pierce E.A. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008;358:2240–2248.
- Meyerson C., Van Stavern G., McClelland C. Leber hereditary optic neuropathy: current perspectives. Clin. Ophthalmol. 2015;9:1165–1176.
- Pei H., Wan X., Hu W. Constructing and detecting a new rAAV2/2-ND4. Eye Sci. 2013;28:55–59.
- Pernet V., Joly S., Dalkara D. Long-distance axonal regeneration induced by CNTF gene transfer is impaired by axonal misguidance in the injured adult optic nerve. Neurobiol. Dis. 2013;51:202–213.
- Shi H., Gao J., Pei H. Adeno-associated virus-mediated gene delivery of the human ND4 complex I subunit in rabbit eyes. Clin. Exp. Ophthalmol. 2012;40:888–894.
- Tseng Y.S., Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second generation Gene delivery vectors. Front. Immunol. 2014;5:9.
- Wan X., Pei H., Zhao M.J. Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy. Sci. Rep. 2016;6:21587.
- Yang S., He H., Zhu Y. Chemical and material communication between the optic nerves in rats. Clin. Exp. Ophthalmol. 2015;43:742–748.
- Yu-Wai-Man P., Griffiths P.G., Chinnery P.F. Mitochondrial optic neuropathies — disease mechanisms and therapeutic strategies. Prog. Retin. Eye Res. 2011;30:81–114.
- Zhang Y., Huang H., Wei S. Characterization of macular thickness changes in Leber's hereditary optic neuropathy by optical coherence tomography. BMC Ophthalmol. 2014;14:105.
Source: PubMed